COMPARATIVE STUDY OF FIXED DOSE COMBINATION OF OLMESARTAN +AMLODIPINE VS TELMESARTAN+METOPROLOL IN STAGE I AND STAGE II HYPERTENSIVE PATIENTS AND ALSO CHECK THEIR EFFECTS ON LIPID METABOLISM

  • Virag Shekhar Shah
  • Pitambar Nilkanth Dighore
  • Hetal Atulbhai Patel
  • Sughosh Vishweshwer Upasani

Abstract

ABSTRACT:

Objectives - Hypertension is the second most severe problem after diabetes in India for the mortality rate. So the primary goal to reduce the mortality is to achieving targeted blood pressure in an individual. Hypertension guidelines recommend the use of 2 agents having complementary mechanisms of action when >1 agent is needed to achieve blood pressure (BP) goals. The objectives of this study are to compare the effect of combination on BP, Lipid Profile, and also to check the safety of both combinations. Methods- This is 16 week open label, study, in which total 70 patient were enrolled. The study was carried out at outpatient department of Indira Gandhi Memorial Hospital Shirpur, Dist- dhule. We include patients which are newly diagnosed to hypertension. Permission from Institutional Human Ethical Committee was obtained. Results- combination therapies shows greater effects on lowering blood pressure than individual monotherapies. In our study we found group II combination shows greater effect than group I combination. The mean BP reduction was found to be ± 31.9/ 13.05 in group I, while in group II ±33.24/15.59 mmHg in group II from baseline after three months follow-up for systolic and diastolic respectively. While comparing lipid profile again Group II shows better results than Group I. Conclusion- These finding shows that the group II shows greater efficacy than group I in all parameter evaluated. The finding also shows that both the combinations are safe and efficacious.

 

Key words- Hypertension, Olmesartan, Amlodipine, Telmesartan, Metoprolol, combination therapy, Lipid Profile, Fixed Dose Combination.

References

1. Thomas G.A.Clinical Classification Of Hypertension, China Medical Journal 2006 Vol 119 (1) Pg No; 80-83
2. Dipiro, J.T., et, al. Pharmacotherapy, A Pathophysiology Approach 2008, McGraw- Hill Publication, 7th Edition, 1347-52.
3. Helms, A.R., Quan, J.D., Harfindal, T.E., Gourley, R.D.,Textbook of Therapeutics-Drug And Disease Management 2006., 8th Edition, Lippincott Williams And Wilkins, Pg No; 1068 – 73.
4. National High Blood Pressure Education Program, the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 1997. Arch Intern Med, Pg No; 2413-46.
5. 2003 European Society of Hypertension–European Society of Cardiology Guidelines for the Management of Arterial Hypertension Guidelines Committee, Journal of Hypertension 2003, 21:1011–53.
6. Gradman A.H., MD, Basile J.N., MD, Carter B.L., PharmD, and Bakris G.L., MD Combination Therapy in Hypertension, Journal of American Society of Hypertension Vol 4(1) 2010 Pg No; 42-50.
7. Fixed Dose Combinations (FDCs) Rational Drug An Update on Rational Drug Use Issue 31 Jan-June 2008. Pg No; 1-8.
8. Bani I. A. MD PhD, Prevalence And Related Risk Factors of Essential Hypertension In Jazan Region, Saudi Arabia, Sudanese Journal of Public Health 2011 Vol 6 (2). Pg No 45-50
9. Mcenieryc.M, Wilkinson I. B.And Avolio A. P, Age, Hypertension and Arterial Function, Clinical and Experimental Pharmacology And Physiology 2007 Vol 34,Pg No; 665–71.
10. Humayun A. Shah A.S. Sultana R., Relation of Hypertension With Body Mass Index and Age in Male and Female Population of Peshawar, Pakistan Department of Physiology, Khyber Medical College, Peshawar, Department of Dentistry, Ayub Medical College Abbottabad- Pakistan Journal of Ayub Med Coll Abbottabad 2009; Vol 21(3) Pg No; 63-65.
11. Kaufman J.S., C. A.Michael, Mufunda J., Forrester T., Wilks R., et, al Relationship Between Blood Pressure And Body Mass Index in Lean Populations, Journal of American Heart Association 1997 Vol 30 Pg No 1511-16.
12. Vaile J. C., Chaudhary S., Osman F., Ross H. F., Fletcher J., Littler W. A., et, al. Effects of Angiotensin II (AT1) Receptor Blockade on Cardiac Vagal Control In Heart Failure, Journal of Clinical Science 2001, Vol 101, Pg No; 559–66.
13. Bangalore S., MD, Sawhney S., MD and Messerli F. H., MD, Relation of Beta-Blocker–Induced Heart Rate Loweringa and Cardio Protection In Hypertension Journal of American College of Cardiology 2008 Vol 52 Pg No; 1482-89.
14. Chrysant S. G., MD, PhD; Melino M, PhD; Karki S., BAMS; Lee J., PhD; and Heyrman R., MD The Combination of Olmesartan Medoxomil and Amlodipine Besylate In Controlling High Blood Pressure: COACH, A Randomized, Double-Blind, Placebo-Controlled, 8-Week Factorial Efficacya and Safety Study. Journal of Clinical Therapeutics Vol 30 2008 Pg No; 587- 604
15. Verma R.B, Chaudhary V. K, Jain V. K, 1987Effect of Calcium Channel Blockers on Serum Lipid Profile. Journal of Post Graduate Medicine Vol 33 (2) Pg No; 65-68
16. Beinartw. M.B. M.R.C.P., Pearsonr. M. M.B., M.R.C.P, Cramp D. G. PhD. Harvard D.M., F.R.C.P. 1979The Effect of Metoprolol on Plasma Lipids Clinical Pharmacology Unit, Royal Northern Hospital, London, N.7 Postgraduate Medical Journal Vol 55, Pg No; 709-11.
Statistics
492 Views | 956 Downloads
How to Cite
Shah, V. S., P. N. Dighore, H. A. Patel, and S. V. Upasani. “COMPARATIVE STUDY OF FIXED DOSE COMBINATION OF OLMESARTAN +AMLODIPINE VS TELMESARTAN+METOPROLOL IN STAGE I AND STAGE II HYPERTENSIVE PATIENTS AND ALSO CHECK THEIR EFFECTS ON LIPID METABOLISM”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 6, no. 7, Aug. 2013, pp. 124-7, https://innovareacademics.in/journals/index.php/ajpcr/article/view/327.
Section
Articles